• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018.第 20 届加拿大西部胃肠癌症共识会议报告；萨斯卡通，萨斯喀彻温省；2018 年 9 月 28 日至 29 日。
Curr Oncol. 2019 Dec;26(6):e773-e784. doi: 10.3747/co.26.5517. Epub 2019 Dec 1.
2
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.共识声明：第16届加拿大西部胃肠道癌年度共识会议；萨斯喀彻温省萨斯卡通；2014年9月5日至6日。
Curr Oncol. 2015 Apr;22(2):e113-23. doi: 10.3747/co.22.2362.
3
Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer.加拿大西部胃肠道共识癌症会议报告-直肠癌新辅助放化疗的全程管理。
Curr Oncol. 2022 Feb 8;29(2):924-927. doi: 10.3390/curroncol29020078.
4
Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.第19届加拿大西部胃肠癌共识会议报告；马尼托巴省温尼伯；2017年9月29日至30日。
Curr Oncol. 2018 Aug;25(4):275-284. doi: 10.3747/co.25.4109. Epub 2018 Aug 14.
5
Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019.第 21 届加拿大西部胃肠道癌症共识会议报告；艾伯塔省卡尔加里；2019 年 9 月 20-21 日。
Curr Oncol. 2021 Sep 21;28(5):3629-3648. doi: 10.3390/curroncol28050310.
6
Report from the 24th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Colorectal Cancer, Richmond, British Columbia, 28-29, October 2022.第 24 届加拿大西部胃肠道癌症共识会议关于结直肠癌的年度报告，2022 年 10 月 28-29 日，不列颠哥伦比亚省里士满。
Curr Oncol. 2023 Aug 29;30(9):7964-7983. doi: 10.3390/curroncol30090579.
7
Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015.第17届加拿大西部胃肠道癌年度共识会议报告；艾伯塔省埃德蒙顿；2015年9月11 - 12日
Curr Oncol. 2016 Dec;23(6):425-434. doi: 10.3747/co.23.3384. Epub 2016 Dec 21.
8
Report from the Western Canadian Gastrointestinal Cancer Consensus Conference Virtual Education Series-Transition from Local to System Therapy and Optimal Sequencing of Systemic Therapy for HCC.加拿大西部胃肠癌共识会议虚拟教育系列报告-从局部治疗向系统治疗的过渡和 HCC 系统治疗的最佳序贯。
Curr Oncol. 2021 Oct 29;28(6):4317-4327. doi: 10.3390/curroncol28060367.
9
Systemic Therapy and Its Surgical Implications in Patients with Resectable Liver Colorectal Cancer Metastases. A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.可切除性肝转移结直肠癌患者的全身治疗及其手术意义。来自加拿大西部胃肠道癌症共识会议的报告。
Curr Oncol. 2022 Mar 8;29(3):1796-1807. doi: 10.3390/curroncol29030147.
10
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.2018年加拿大东部胃肠道癌共识会议
Curr Oncol. 2019 Oct;26(5):e665-e681. doi: 10.3747/co.26.5193. Epub 2019 Oct 1.

引用本文的文献

1
Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with Wild-Type Left-Sided Tumours in Canada.评估加拿大野生型左侧肿瘤转移性结直肠癌患者治疗模式和临床结局的真实世界研究。
Curr Oncol. 2023 Sep 6;30(9):8220-8232. doi: 10.3390/curroncol30090596.

本文引用的文献

1
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).随机试验伊立替康和西妥昔单抗与或无维莫非尼在 BRAF 突变转移性结直肠癌（SWOG S1406）。
J Clin Oncol. 2021 Feb 1;39(4):285-294. doi: 10.1200/JCO.20.01994. Epub 2020 Dec 23.
2
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial.一线西妥昔单抗联合亚叶酸、氟尿嘧啶和奥沙利铂（FOLFOX-4）与 FOLFOX-4 一线治疗野生型转移性结直肠癌患者的疗效和耐受性：开放标签、随机、III 期 TAILOR 试验。
J Clin Oncol. 2018 Oct 20;36(30):3031-3039. doi: 10.1200/JCO.2018.78.3183. Epub 2018 Sep 10.
3
Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer.治疗后监测检测强度与结直肠癌患者复发检测的关系。
JAMA. 2018 May 22;319(20):2104-2115. doi: 10.1001/jama.2018.5816.
4
Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial.更频繁与不那么频繁的随访检测对 II 期或 III 期结直肠癌患者总死亡率和结直肠癌特异性死亡率的影响：COLOFOL 随机临床试验。
JAMA. 2018 May 22;319(20):2095-2103. doi: 10.1001/jama.2018.5623.
5
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.四项随机帕尼单抗研究中 RAS 野生型转移性结直肠癌患者二线或以上治疗结局与所有治疗线中 RAS 突变患者的原发肿瘤位置的影响。
Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.
6
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.局部晚期直肠癌的全新辅助治疗的采用。
JAMA Oncol. 2018 Jun 14;4(6):e180071. doi: 10.1001/jamaoncol.2018.0071.
7
Comparison of transanal endoscopic microsurgery with or without neoadjuvant therapy and standard total mesorectal excision in the treatment of clinical T2 low rectal cancer: a meta-analysis.经肛门内镜显微手术联合或不联合新辅助治疗与标准全直肠系膜切除术治疗临床T2期低位直肠癌的比较：一项Meta分析
Oncotarget. 2017 Oct 26;8(70):115681-115690. doi: 10.18632/oncotarget.22091. eCollection 2017 Dec 29.
8
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.纳武利尤单抗联合伊匹单抗治疗错配修复缺陷/微卫星高度不稳定转移性结直肠癌的持久临床获益。
J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.
9
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.根据肿瘤位置而非侧别对结直肠癌进行分类突出了突变特征和共识分子亚型的连续性。
Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.
10
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.III 期结肠癌患者接受 FOLFOX 辅助化疗时错配修复缺陷状态的作用：来自 2 项随机临床试验的汇总分析。
JAMA Oncol. 2018 Mar 1;4(3):379-383. doi: 10.1001/jamaoncol.2017.2899.

第 20 届加拿大西部胃肠癌症共识会议报告；萨斯卡通，萨斯喀彻温省；2018 年 9 月 28 日至 29 日。

Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018.

机构信息

Saskatoon Cancer Centre, Saskatchewan Cancer Agency, Saskatoon, SK.

CancerCare Manitoba, Winnipeg, MB.

出版信息

Curr Oncol. 2019 Dec;26(6):e773-e784. doi: 10.3747/co.26.5517. Epub 2019 Dec 1.

DOI:10.3747/co.26.5517
PMID:31896948
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6927778/
Abstract

The 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference was held in Saskatoon, Saskatchewan, 28-29 September 2018. This interactive multidisciplinary conference is attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba) who are involved in the care of patients with gastrointestinal cancers. In addition, invited speakers from other provinces participate. Surgical, medical, and radiation oncologists, and allied health care professionals participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of colorectal cancers.

摘要

第 20 届加拿大西部胃肠道癌症共识会议于 2018 年 9 月 28 日至 29 日在萨斯喀彻温省萨斯卡通市举行。该互动式多学科会议由来自加拿大西部（不列颠哥伦比亚省、艾伯塔省、萨斯喀彻温省和马尼托巴省）的胃肠道癌症患者护理医护人员参加。此外，还邀请了来自其他省份的演讲者参加。外科医生、内科医生和放射肿瘤学家以及相关的医疗保健专业人员参加了演讲和讨论会议，目的是制定这里提出的建议。本共识声明涉及结直肠癌管理中的当前问题。